2012 financial year: Bachem clearly tops prior-year results at all levels

March 15, 2013
  • Healthy top-line growth of 7.9%
  • EBIT up sharply to 22.0 million CHF (+48.4%)
  • Margins of 28.2% (EBITDA) and 14.0% (EBIT)
  • Disproportionate bottom-line growth to 15.3 million CHF (+62.6%)
  • Strong business with NCEs, research chemicals still under pressure, improved results from generic peptides
  • Steady growth in sales and profits forecast